Welcome to our dedicated page for OMEROS SEC filings (Ticker: OMER), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OMEROS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OMEROS's regulatory disclosures and financial reporting.
OMEROS CORP (OMER) reported that director Joseph L. Schocken received a grant of 30,000 stock options to purchase common stock. The options have an exercise price of $13.71 per share and expire on August 11, 2036. They vest in equal annual installments over three years beginning on the first anniversary of the grant date, and following this grant he holds 30,000 derivative securities directly.
OMEROS CORP (OMER) director Joseph L. Schocken filed an initial Form 3 reporting his beneficial ownership of the company’s common stock. He reports 380,472 shares held directly, and additional indirect holdings of 145,100 shares through Tranceka, LLC and 2,510 shares through Tranceka Holdings, LLC. Tranceka, LLC is wholly owned by Schocken and his spouse and is the sole owner of Tranceka Holdings, LLC.
Omeros Corp executive David J. Borges reported an option exercise and same-day sale of common stock. On August 13, 2026, he exercised 5,000 stock options with an exercise price of $3.93 per share, acquiring 5,000 common shares, and then sold 5,000 common shares at $16.95 per share in an open-market transaction. The filing states that the sale was made under a previously established Rule 10b5-1 trading plan, and that following the option exercise, 15,000 options of this grant remained outstanding, continuing to vest in equal monthly installments from a vesting commencement date of April 1, 2022.
Omeros Corporation expanded its Board of Directors to nine members and appointed Joseph Schocken as a director effective August 12, 2026. His initial term runs until the Company’s 2027 annual meeting of shareholders or earlier resignation or removal.
Schocken, 79, is a private investor and founder and president of Tranceka Capital, LLC, with a long history in investment banking and public-company leadership. He was also a driving participant in national economic policy discussions and the JOBS Act and currently serves as chairman of Taqtile, Inc.
Under Omeros’ non-employee director compensation policy, Schocken received a stock option to purchase 30,000 shares of common stock on his appointment date and will be covered by the Company’s standard director indemnification agreement. He joins the Board’s Audit Committee, and the Company states he has no disclosable material interests in related-party transactions.
Omeros Corporation reported its first commercial quarter for YARTEMLEA, generating $28.5 million in product sales for the quarter and $38.4 million for the first half of 2026, compared with no product sales in 2025. Net income for the quarter was $13.2 million and for the first six months $69.3 million, versus net losses of $25.4 million and $58.9 million in the prior‑year periods, helped by a $84.6 million net gain on changes in fair value of financial instruments and income from discontinued OMIDRIA royalties.
Cash and cash equivalents were $2.0 million with $130.0 million in short‑term investments as of June 30, 2026. Net cash used in operating activities was $10.4 million for the first half. The OMIDRIA contract royalty asset totaled $116.5 million, offset by an OMIDRIA royalty obligation of $157.9 million. Omeros repurchased portions of its 2029 convertible notes, leaving $54.8 million principal outstanding, and shareholders’ deficit narrowed to $51.3 million from $121.2 million at year‑end 2025.
Omeros Corporation reported strong second-quarter 2026 results driven by the U.S. launch of YARTEMLEA for TA-TMA. YARTEMLEA generated $32.2 million in gross revenue and $28.5 million in net product sales, a 190% increase in gross revenue from $11.1 million in the first quarter of 2026.
GAAP net income was $13.2 million, or $0.18 per basic share, versus a net loss of $25.4 million a year earlier, aided by an $11.4 million non-cash gain on financial instruments and $6.6 million income from discontinued operations. Non-GAAP adjusted net income was $1.8 million, or $0.02 per share. At June 30, 2026, cash and short-term investments totaled $132.0 million, and operating cash flow was $4.1 million for the quarter. The company repurchased $30.5 million principal of 2029 convertible notes, cutting outstanding principal to $40.3 million, eliminating $8.6 million in future interest and reducing potential dilution from 11.4 million to 6.5 million shares, and also retired 0.8 million common shares for $9.9 million. Omeros disclosed a negative CHMP opinion on its narsoplimab MAA in Europe and has requested re-examination while advancing multiple pipeline programs.
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of 5,961,792 shares of Omeros Corp common stock. This position represents 8.2% of the outstanding common shares.
BlackRock reports sole voting power over 5,835,368 shares and sole dispositive power over 5,961,792 shares, with no shared voting or dispositive power. Various underlying clients and funds have economic interests in these shares, but no single person has more than five percent of Omeros’ total outstanding common stock.
Omeros Corporation reported that Chairman, CEO & President Gregory A. Demopulos received a grant of 1,000,000 stock options on July 22, 2026. The options have an exercise price of $9.84 per share, expire on July 22, 2036, and are exercisable into an equal number of common shares.
According to the vesting schedule, one-third of the options vest and become exercisable on August 1, 2027, with the remaining options vesting in 32 equal monthly installments on the first day of each month thereafter. Following this grant, he directly holds stock options for 1,000,000 shares.
Omeros Corp granted VP and General Counsel Peter B. Cancelmo 105,000 stock options for common stock on July 22, 2026. The options have a $9.84 per-share exercise price and expire on July 22, 2036. One-third vests on August 1, 2027, with the remaining shares vesting in 32 equal monthly installments thereafter.